UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
WASHINGTON, D.C. 20549 |
____________ |
FORM 8-K |
CURRENT REPORT |
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Date of Report (Date of earliest event reported): February 21, 2017 |
SHIRE PLC |
(Exact name of registrant as specified in its charter) |
Jersey, Channel Islands | 0-29630 | 98-0601486 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
5 Riverwalk, Citywest Business Campus, Dublin 24, Republic of Ireland |
Registrant’s telephone number, including area code: +353 1 429 7700 |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.): |
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events
Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibit is filed herewith:
99.1 Press Release dated February 21, 2017
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Shire plc | ||||
By: | /s/ W R Mordan | |||
Name: | Bill Mordan | |||
Title: | Company Secretary |
Date: February 21, 2017
EXHIBIT INDEX
Exhibit No. |
Description | |
99.1 | Press Release dated February 21, 2017 |
Exhibit 99.1
Press
Release www.shire.com |
![]() |
Director/PDMR Shareholding
February 21, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by person discharging managerial responsibilities
1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”) | ||
a) | Name | Perry Sternberg | |
2. | Reason for the notification | ||
a) | Position / status | Head of US Commercial - PDMR | |
b) | Initial notification / amendment | Initial notification | |
3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Shire plc | |
b) | LEI | 54930005LQRLI2UXRQ59 | |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
| |
Identification code | ISIN: US82481R1068 | ||
b) | Nature of the transaction | Exercise of Stock Appreciation Rights (“SARs”) in respect of 3,558 notional ADSs awarded under the Shire Portfolio Share Plan and consequent receipt of ADSs. (Details of related disposals of ADSs are referenced in the sections below.) | |
c) | Price(s) and volume(s) | Exercise price(s) | Volume(s) ADSs received |
$119.27 | 1,202 | ||
d) |
Aggregated information
- Aggregated volume
- Price
|
N/A (single transaction) | |
e) | Date of the transaction | February 17, 2017 | |
f) | Place of the transaction | N/A |
5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”) | |
Identification code | ISIN: US82481R1068 | ||
b) | Nature of the transaction |
Disposals of ADSs (Disposals marked with * are in relation to the exercise of SARs referenced in section 4. above. Part of the proceeds of these disposals were used to satisfy personal tax liabilities arising from the exercise of the SARs.) | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
$180.87* | 200 | ||
$180.73* | 200 | ||
$180.73* | 200 | ||
$180.28 | 99 | ||
$180.29 | 300 |
d) |
Aggregated information - Aggregated volume - Price |
Weighted average price | Volume |
$180.58 | 999 | ||
e) | Date of the transaction | February 17, 2017+ | |
f) | Place of the transaction | NYSE (BQT) |
6. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”) | |
Identification code | ISIN: US82481R1068 | ||
b) | Nature of the transaction | Disposals of ADSs in relation to the exercise of SARs referenced in section 4. above. Part of the proceeds of these disposals were used to satisfy personal tax liabilities arising from the exercise of the SARs. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
$180.86 | 100 | ||
$180.85 | 100 | ||
$180.85 | 185 | ||
$180.85 | 100 | ||
$180.71 | 17 |
d) |
Aggregated information - Aggregated volume - Price |
Weighted average price | Volume |
$180.85 | 502 | ||
e) | Date of the transaction | February 17, 2017 | |
f) | Place of the transaction | NASDAQ | |
7. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”) | |
Identification code | ISIN: US82481R1068 | ||
b) | Nature of the transaction | Disposal of ADSs in relation to the exercise of SARs referenced in section 4. above. Part of the proceeds of this disposal were used to satisfy personal tax liabilities arising from the exercise of the SARs. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
$180.76 | 100 | ||
d) |
Aggregated information - Aggregated volume - Price |
N/A (single transaction) | |
e) | Date of the transaction | February 17, 2017 | |
f) | Place of the transaction | Bats BYX |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations | ||
Ian Karp | ikarp@shire.com | +1 781 482 9018 |
Robert Coates | rcoates@shire.com | +44 1256 894874 |
Media | ||
Lisa Adler | lisa.adler@shire.com | +1 617 588 8607 |
Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com